NK effector mechanisms during NK-lymphoma interactions
NK effector mechanisms during NK-lymphoma interactions
批准号:
7258867
负责人:
Charles L. Sentman
金额:
$26.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2009-06-30
关键词:
AntibodiesCancer VaccinesCell CommunicationCommunicable DiseasesCytotoxic T-LymphocytesDataFc ReceptorGenerationsGrowthHistocompatibility Antigens Class IImmuneImmune responseImmunityImmunotherapyIn VitroInflammatoryLymphomaMHC Class I GenesMacrophage ActivationModelingMusNK Cell ActivationNatural Killer CellsNormal CellPathway interactionsPersonal SatisfactionPhaseProductionResearch ProposalsRoleSeriesSiteSystemT-LymphocyteTestingThinkingTransgenic MiceTumor Immunitycell injuryfightingin vivokillingsmacrophageneoplastic cellpreventreceptorresearch studyresponsetumor
中文摘要
描述(申请人提供):众所周知,NK细胞可以在体外和体内杀死肿瘤细胞。人们还知道,通过 MHC I 类分子与 NK 细胞上的抑制性受体的相互作用,可以阻止 NK 细胞杀死肿瘤细胞。我们的假设是,早期 NK 细胞与肿瘤细胞的相互作用对于确定 NK 细胞是否促进抗肿瘤免疫或阻止抗肿瘤免疫很重要。这些相互作用可能在肿瘤生长阶段的早期很重要。此外,肿瘤细胞可能可以阻止 NK 细胞效应机制,从而阻止抗肿瘤免疫反应并促进肿瘤存活。数据表明,NK 细胞是针对传染病和肿瘤的先天防御的一部分,并且 NK 细胞可以影响下游免疫。本研究计划的目的是研究 NK 细胞可以在多大程度上改变宿主对肿瘤的反应,以及 NK 细胞激活宿主巨噬细胞和溶细胞 T 细胞对抗肿瘤细胞的机制。我们假设 NK 细胞激活对于巨噬细胞的正确激活和产生针对肿瘤细胞的长期溶细胞 T 细胞很重要。我们的具体目标是:1) 确定 NK 细胞抑制性受体阻止宿主抗肿瘤反应产生的程度。我们将使用抗受体抗体和受体转基因小鼠来确定这些抑制性受体对抗肿瘤免疫的影响。 2) 确定NK细胞效应机制在不同巨噬细胞效应功能(即M1和M2巨噬细胞)生成中的作用。我们将利用基因改造小鼠的体外和体内系统来测试关键效应分子和途径。 3)确定NK细胞被诱导激活局部宿主抗肿瘤免疫反应的程度。我们将尝试用肿瘤特异性抗体改变局部 NK 细胞活化并诱导炎症巨噬细胞。这些实验将涉及两种小鼠淋巴瘤模型:RMA 和 BW-Sp3 肿瘤细胞。我们的目标是了解 NK 与肿瘤细胞的相互作用如何促进或无法促进有效的抗肿瘤免疫反应。这些数据将对免疫疗法和肿瘤疫苗产生影响,并为开发更有效的肿瘤免疫的方法提供建议。
英文摘要
DESCRIPTION (provided by applicant): It is well known that NK cells can kill tumor cells in vitro and in vivo. It is also known that NK cells can be prevented from killing tumor cells by the interaction of MHC class I molecules and inhibitory receptors on NK cells. Our hypothesis is that the early NK cell-tumor cell interaction is important in determining whether NK cells promote anti-tumor immunity or prevent anti-tumor immunity. These interactions are likely to be important early in the growth phase of a tumor. Furthermore, it may be possible that tumor cells can prevent NK cell effector mechanisms and thus prevent anti-tumor immune responses and promote tumor survival. Data suggest that NK cells are a part of the innate defense against infectious diseases and tumors, and NK cells can influence downstream immunity. The aim of this research proposal is to investigate the extent to which NK cells can alter host responses to tumors and the mechanisms that NK cells employ to activate host macrophages and cytolytic T cells against tumor cells. We hypothesize that NK cell activation is important for the proper activation of macrophages and the production of long-term cytolytic T cells against tumor cells. Our specific aims are: 1) to determine the extent to which NK cell inhibitory receptors prevent the generation of a host anti-tumor response. We will use anti-receptor antibodies and receptor transgenic mice to determine the influence of these inhibitory receptors on anti-tumor immunity. 2) To determine the role of NK cell effector mechanisms in the generation of different macrophage effector functions, so called M1 and M2 macrophages. We will utilize in vitro and in vivo systems with genetically altered mice to test key effector molecules and pathways. 3) To determine the extent to which NK cells can be induced to activate local host anti-tumor immune responses. We will attempt to alter local NK cell activation with tumor specific antibodies and induce inflammatory macrophages. These experiments will involve two murine lymphoma models: RMA andBW-Sp3 tumor cells. We aim to understand how NK-tumor cell interactions promote or fail to promote effective anti-tumor immune responses. These data will have implications for immunotherapy and tumor vaccines and suggest ways to develop more potent tumor immunity.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.
TRAIL/DR5 在 NK 细胞介导的 T 细胞树突状细胞交叉启动负调节中发挥着关键作用。
DOI:
10.4049/jimmunol.1003879
发表时间:
2011
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Iyori,Mitsuhiro, Zhang,Tong, Pantel,Haddon, Gagne,BethanyA, Sentman,CharlesL]
通讯作者:
Sentman,CharlesL
Immunomodulatory and behavioral effects of CAR T regulatory cell therapy for Alzheimer's Disease”.
-
批准号:10633721
-
项目类别:
-
资助金额:$24.6万
-
财政年份:2023
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric antigen receptor T regulatory cells as therapy for Alzheimer's Disease
-
批准号:10025408
-
项目类别:
-
资助金额:$45.1万
-
财政年份:2020
-
负责人:Charles L. Sentman
-
依托单位:
Cell therapy using neurodegenerative disease modifying molecules (NDMMs) as a means to modulate oxidative damage and neuronal survival in ALS
-
批准号:10038210
-
项目类别:
-
资助金额:$45.1万
-
财政年份:2020
-
负责人:Charles L. Sentman
-
依托单位:
A novel NKG2D-specific BiTE cancer immunotherapy
-
批准号:8437514
-
项目类别:
-
资助金额:$33.51万
-
财政年份:2013
-
负责人:Charles L. Sentman
-
依托单位:
A novel NKG2D-specific BiTE cancer immunotherapy
-
批准号:8601295
-
项目类别:
-
资助金额:$32.61万
-
财政年份:2013
-
负责人:Charles L. Sentman
-
依托单位:
A novel NKG2D-specific BiTE cancer immunotherapy
-
批准号:8974814
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2013
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric NKG2D receptors in ovarian cancer immunotherapy
-
批准号:8074911
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2008
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric NKG2D receptors in ovarian cancer immunotherapy
-
批准号:7821443
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2008
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric NKG2D receptors in ovarian cancer immunotherapy
-
批准号:7519745
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2008
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric NKG2D receptors in ovarian cancer immunotherapy
-
批准号:7665171
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2008
-
负责人:Charles L. Sentman
-
依托单位:
Chimeric NKG2D receptors in ovarian cancer immunotherapy
-
批准号:8267726
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2008
-
负责人:Charles L. Sentman
-
依托单位:
NK effector mechanisms during NK-lymphoma interactions
-
批准号:6668108
-
项目类别:
-
资助金额:$28.12万
-
财政年份:2003
-
负责人:Charles L. Sentman
-
依托单位:
NK effector mechanisms during NK-lymphoma interactions
-
批准号:6908214
-
项目类别:
-
资助金额:$28.12万
-
财政年份:2003
-
负责人:Charles L. Sentman
-
依托单位:
NK effector mechanisms during NK-lymphoma interactions
-
批准号:6760898
-
项目类别:
-
资助金额:$28.12万
-
财政年份:2003
-
负责人:Charles L. Sentman
-
依托单位:
NK effector mechanisms during NK-lymphoma interactions
-
批准号:7065153
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2003
-
负责人:Charles L. Sentman
-
依托单位:
Immunology & Cancer Immunotherapy (ICI)
-
批准号:8804020
-
项目类别:
-
资助金额:$7.0万
-
财政年份:1997
-
负责人:Charles L. Sentman
-
依托单位:
Immunobiology of Myeloid and Lymphoid Cells
-
批准号:9564482
-
项目类别:
-
资助金额:$42.5万
-
财政年份:1990
-
负责人:Charles L. Sentman
-
依托单位:
Immunobiology of Myeloid and Lymphoid Cells
-
批准号:8874825
-
项目类别:
-
资助金额:$40.57万
-
财政年份:1990
-
负责人:Charles L. Sentman
-
依托单位:
Immunobiology of Myeloid and Lymphoid Cells
-
批准号:8337922
-
项目类别:
-
资助金额:$39.96万
-
财政年份:1990
-
负责人:Charles L. Sentman
-
依托单位:
Immunobiology of Myeloid and Lymphoid Cells
-
批准号:8486353
-
项目类别:
-
资助金额:$39.52万
-
财政年份:1990
-
负责人:Charles L. Sentman
-
依托单位:
海外基金